Last reviewed · How we verify
isatuximab SAR650984
Isatuximab is a monoclonal antibody that targets CD38, a protein found on the surface of certain cancer cells.
Isatuximab is a monoclonal antibody that targets CD38, a protein found on the surface of certain cancer cells. Used for Relapsed or refractory multiple myeloma, Relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | isatuximab SAR650984 |
|---|---|
| Also known as | Sarclisa |
| Sponsor | Sanofi |
| Drug class | Monoclonal antibody |
| Target | CD38 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to CD38, isatuximab triggers an immune response that helps to kill cancer cells. This mechanism is thought to be particularly effective in treating certain types of blood cancers, such as multiple myeloma.
Approved indications
- Relapsed or refractory multiple myeloma
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Infusion-related reactions
- Fatigue
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma (PHASE2)
- ELISA in Relapsed/Refractory MM (PHASE2)
- Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (PHASE1)
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis (PHASE1)
- Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (PHASE3)
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- isatuximab SAR650984 CI brief — competitive landscape report
- isatuximab SAR650984 updates RSS · CI watch RSS
- Sanofi portfolio CI